Literature DB >> 10334881

Role of nitric oxide, vasoactive intestinal polypeptide, and ATP in inhibitory neurotransmission in human jejunum.

M M Murr1, B M Balsiger, G Farrugia, M G Sarr.   

Abstract

BACKGROUND: Inhibitory neurotransmission in the human intestine is poorly understood. This study was undertaken to determine the role of nitric oxide (NO), adenosine triphosphate (ATP), and vasoactive intestinal polypeptide (VIP) in inhibitory neurotransmission in human jejunal circular muscle strips.
METHODS: In vitro response of precontracted (10(-5) M substance P) normal human jejunal muscle strips to electric field stimulation (EFS) under adrenergic and cholinergic receptor blockade was evaluated. Selective neural blockade was obtained by the NO synthase inhibitor l-NG-nitroarginine methyl ester (l-NAME, 10(-3) M), VIP receptor antagonist (4-Cl-d-Phe6Leu17-VIP, 10(-7) M), P2 purinergic receptor blocker suramin (3 x 10(14) M), or the calcium-dependent potassium channel blocker apamin (10(-6) M). Force generated in response to EFS was quantitated and analyzed statistically.
RESULTS: Exogenous NO and ATP dose-dependently inhibited contractile activity and relaxed muscle strips with a concentration yielding a 50% effect (ED50) of 4.5 +/- 2.9 x 10(-6) M and 3.3 +/- 1.3 x 10(-4) M, respectively. EFS resulted in relaxation of precontracted muscle strips in all groups. When compared with controls, relaxation was decreased but not abolished by l-NAME (-0.12 +/- 0.03 vs -0.33 +/- 0. 05, -0.07 +/- 0.03 vs -0.34 +/- 0.05, and 0.04 +/- 0.03 vs -0.30 +/- 0.04 at 2, 5, and 10 Hz, respectively, P < 0.011). d-NAME (inactive stereoisomer of l-NAME), 4-Cl-d-Phe6Leu17-VIP, suramin, and apamin did not alter EFS-induced relaxation.
CONCLUSIONS: Inhibition of NO synthesis by l-NAME reduced the inhibitory response to EFS, whereas blocking ATP and VIP receptors or other effector pathways had no effect. Our findings indicate that although NO plays a predominant role in inhibitory neurotransmission in human jejunal circular muscle, another neurotransmitter(s) appears to be involved as well. These data may impact on understanding mechanisms of disorders of gut dysmotility. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334881     DOI: 10.1006/jsre.1999.5590

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Intestinal expressions of eNOSmRNA and iNOSmRNA in rats with acute liver failure.

Authors:  J M Qin; Y D Zhang
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Vagal neural crest provides inhibitory neurotransmission to the chick embryo cloaca.

Authors:  Anne-Marie O' Donnell; Prem Puri
Journal:  Pediatr Surg Int       Date:  2008-12       Impact factor: 1.827

3.  Small intestinal motility in soluble guanylate cyclase alpha1 knockout mice: (Jejunal phenotyping of sGCalpha1 knockout mice).

Authors:  Ingeborg Dhaese; Gwen Vanneste; Patrick Sips; Emmanuel S Buys; Peter Brouckaert; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-12-04       Impact factor: 3.000

4.  Inhibitory pathways in the circular muscle of rat jejunum.

Authors:  Gwen Vanneste; Patrick Robberecht; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

5.  Gene therapy of Cav1.2 channel with VIP and VIP receptor agonists and antagonists: a novel approach to designing promotility and antimotility agents.

Authors:  Xuan-Zheng Shi; Sushil K Sarna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-08       Impact factor: 4.052

6.  High-fat diet-induced obesity alters nitric oxide-mediated neuromuscular transmission and smooth muscle excitability in the mouse distal colon.

Authors:  Yogesh Bhattarai; David Fried; Brian Gulbransen; Mark Kadrofske; Roxanne Fernandes; Hui Xu; James Galligan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-06-10       Impact factor: 4.052

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.